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Neonatesa b s t r a c t
Background: Peroxisome Proliferator-Activated Receptor gamma (PPARc) is a ligand-dependent tran-
scription factor involved in inflammatory process. PPAR-c gene was mentioned as having a modulating
role in the pathological status of sepsis.
The present study aimed to make a correlation between The Pro12Ala polymorphism in PPAR-c gene and
occurrence of neonatal sepsis and its severity among a sample of Egyptian neonates suffering sepsis.
Subjects and methods: This case-control study included 30 neonates (11 females and19 males) newly
admitted with neonatal sepsis at the intensive care unit (NICU) (mean age 10.3 days ± 6.23). The control
group included 50 age and sex matched neonates (23 females and 27 males) (mean age
10.20 days ± 5.36 days). All the neonates (preterm and full term) included were with clinical signs and
laboratory data consistent with neonatal sepsis. Genotyping for PPARc gene region harboring the
Pro12Ala variant locus were carried out using Tetra ARMS technique.
Results: About 56.7% of the patients group was homozygote (GG) for polymorphic locus (coding for
Alanine/Alanine) while 30% was heterozygote for polymorphic locus (CG) (coding for Proline/Alanine)
and up to 13.3% was homozygote for the polymorphic locus (CC) (coding for Proline/Proline).
Compared to the control group where homozygotes for CC were the most prevalent (90%) and the CG
were 10% with absence of GG genotypes. There was a strong statistical significant difference between
patients and the normal control group as regards prevalence of PPAR-c gene polymorphism in occurrence
of neonatal sepsis and its severity. Also, there were strong relation between genotype GG and low birth
weight, neonatal fever, prematurity and depressed neonatal reflexes.
Conclusion: PPAR-c gene has been suggested to be a candidate gene for neonatal sepsis. Therefore,
Pro12Ala polymorphism might be useful in predicting the risk factor of neonatal sepsis and its
severity.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sepsis clinically may involve a massive systemic inflammatory
response resulting in septic shock, multiple organ failure, and
death [1]. Premature and ill infants are more susceptible to sepsis
disease; thus, considerable care is required in those infants so that
sepsis can be effectively identified and treated [2].
Peroxisome proliferator-activated receptor (PPAR) are ligand
activated transcription factors that belong to the nuclear hormone
receptor superfamily [3], which include 3 subfamilies (PPARa,PPARb/d, PPAR-c). These transcription factors play a major role in
sepsis and development of inflammatory disease. Peroxisome
proliferator-activated receptor gamma (PPAR-c) was described as
playing a role in modulating the pathological status of sepsis by
regulating energy metabolism, inflammation, and immune cell
function [4]. PPAR-c regulate inflammatory status by controlling
the differentiation of macrophages and monocytes and by inhibit-
ing the expression of inflammatory cytokines, such as interleukin-
1 beta (IL-1b), tumor necrosis factor alpha (TNF-a), inducible
cyclooxygenase-2 (COX-2). Therefore, PPAR-c seems to be a candi-
date gene for sepsis [5].
SNP in the PPAR-c gene rs1801282 is considered as a major
functional polymorphism in codon 12 of exon B. This SNP leads a
mutation in which Proline is replaced by Alanine [6].
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The Pro12Ala Polymorphism in PPAR-c Gene and occurrence of
neonatal sepsis and its severity among a sample of Egyptian neo-
nates suffering sepsis.Fig. 1. PCR Products of a fragment from the PPARc gene for the detection of the
Pro12Ala mutation. Lane 1: show the mutant homozygous genotype (GG). Lane 2:
show the heterozygous genotype (GC). Lane 3: show the normal homozygous
genotype (CC). M: Marker 50 bp ladder.2. Patients and methods
2.1. Patients
This case-control study included 30 neonates (11 females and19
males) newly admitted with neonatal sepsis at the intensive care
unit (NICU) in the age range from 2 to 25 days (mean
10.3 days ± 6.23). The control group included 30 age and sex
matched neonates (23 females and 27 males) (mean age
10.20 days ± 5.36 with range from 2 to 20 days). All the neonates
(preterm and full term) included in the study were with clinical
signs and laboratory data consistent with neonatal sepsis. Exclu-
sion criteria included neonates with lethal or major congenital
anomalies and neonates with suspected clinical features of chro-
mosomal disorders.
Consents from all patients’ and controls’ parents/guardians
were taken to approve sharing in the study after full description
of the steps and aim of the study. The work has been carried out
in accordance with the code of Ethics of the World Medical associ-
ation (Declaration of Helsinki) for experiments involving humans
and the Ethical Committee of Ain Shams University” for the same
purpose.
- Detailed maternal and obstetric history were obtained regard-
ing gravidity and parity, obstetric history including mode and
place of delivery, premature rupture of membrane > 18 h, dura-
tion of labor, maternal pyrexia >38 C or maternal illness.
Neonatal history included gestational age confirmed by ‘‘Ballard
score” [7], birth weight, onset of neonatal sepsis and duration of
hospital stay.
- All of the neonates were subjected to complete neonatal exam-
ination: Newborns with evidence of at least one organ dysfunc-
tion and those with at least 2 of the following 4 criteria defining
systemic inflammatory response syndrome (SIRS) were
included in the study.
 Core temperature >38.5 or <36.0 C.
 Tachycardia, defined as a mean heart rate >2 SD above normal
for age, and bradycardia, defined as a mean heart rate <10th
percentile for age.
 Mean respiratory rate >2 SD above normal for age [8].
2.2. Methods
Sepsis screen by qualitative CRP by CRP card, ESR, CBC (Leuko-
cyte count elevated or depressed for age or >10% immature neu-
trophils of the total neutrophils count).
Genotyping: DNAwas extracted from 250 ll peripheral blood by
Chemagic DNA Blood250 Kit and Chemagic magnetic stand 2  12
(Art. No. CMG-300) (Chemagen Technology, PerkinElmer). The
eluted DNAwas stored at20 C till application. Peroxisome prolif-
erator activated receptor-c gene region harboring the Pro12Ala
variant locus was amplified using the following primers [9]:
Tetra primers: Forward tetra primer: 50-GAA ACT CTG GGA GAT
TCT CCT ATT GTC C-30, Reverse tetra primer: 50-GTA TCA GTG AAG
GAA TCG CTT TCA GC-30. (C allele 221 bp while G allele 288 bp).
Outer primers 455 bp: Forward outer primer: 50-AAC TTT TTG
TCA CAG CTG GCT CCT AAT A-30, Reverse outer primer: 50-CAA
CGA GCT AAG CAT TAA AAT ACT GGA-30.
Tetra-primer ARMS-PCR method was used for amplification of
approximately 200 ng of template genomic DNA in a 25 lL. PCRreaction volume containing 20 pmol of each of the 2 inner primers,
2 pmol of each of the 2 outer primers. 1.5 mM MgCl2, 400 lM of
each dNTP, 2 U Hot start Taq polymerase, 10 mM Tris-HCl and 1
PCR buffer. The PCR program (S24 thermal cycler, Quanta
Biotech-England, UK) was: Predenaturation at 95 C for 5 min
followed by 35 cycles of 95 C for 60 s, 63 C for 60 s and 72 C for
60 s, and followed by final extension at 72 C for 7minutes. This
yielded an amplified PCR fragment of 221 bp in length for the frag-
ment harboring C allele and 288 bp for G allele in addition to 455 bp
from the two outer primers. The genotypes of the PCR products
were subjected to electrophoresis on 2% high resolution agarose
gels stained with ethidium bromide in 1x Tris-EDTA (ethylenedi-
amine tetraacetic acid)-Borate buffer (TBE) against 50 bp ladder
molecular weight GeneRulerTM 50 bp DNA ladder (FermentasTM,
#SM0373, Thermo Scientific/Fermentas, Vilnius, Lithuania). The
PCR products were all documented by Gel Documentation System
and Software for DNA analysis (InGenius SyngeneTM – UK) (Fig. 1).2.3. Statistics
The distribution of genotypes and allele frequencies were all
statistically compared in all patients versus healthy controls (Pack-
age for Social Science-IBM SPSS-version 20). Qualitative data were
presented as number and percentages while quantitative data
were presented as mean, standard deviations and ranges.
Kolmogrov-Smirnov test of normality was used to assess the distri-
bution of the studied data and found with normal distribution in
all parameters. The comparison between two groups with qualita-
tive data were done by using Chi-square test and/or Fisher exact test
was used instead of Chi-square test when the expected count in
any cell was found less than 5. The comparison between two inde-
pendent groups regarding quantitative data with parametric distri-
bution was done by using Independent t-test. The confidence
interval was set to 95% and the margin of error accepted was set
to 5%. So, the p-value was considered significant as (P < 0.05: Sig-
nificant, P < 0.01: Highly significant) and P > 0.05: Non significant.3. Results
The present study included 30 neonates with sepsis and 30
healthy controls of matching age and sex. There were no significant
differences between patients and control regarding age and sex.
About 56.7% of the patients group was homozygote (GG) for
polymorphic locus (coding for Alanine/Alanine) while 30% was
heterozygote for polymorphic locus (CG) (coding for Proline/Ala-
nine) and up to 13.3% was homozygote for the polymorphic locus
(CC) (coding for Proline/Proline). There was a highly significant sta-
tistical relationship between the pro 12 Ala polymorphism in
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wild type allele (C) in homozygosity (CC) and in heterozygosity
(CG) was 28.33% while the incidence of mutant allele (G) in
homozygosity (GG) and in heterozygosity (GC) was 71.67%. The
tendency of allele G to segregate in homozygosity was more than
allele C (56.66% vs. 13.33%). Among the patients group; the preva-
lence of the homozygote genotype for GG was 56.7% followed by
the heterozygote for CG genotype 30% then the homozygotes for
CC genotype which appeared in a percentage of 13.3% compared
to the control group where homozygotes for CC were the most
prevalent (90%) and the CG were 10% with absence of GG geno-
types. There was a strong statistical significant difference betweenTable 3
Correlation between genotypes, and mean values for laboratory findings among patients g
Mean value Homozygote (CC) Proline/
Proline (221 bp)
Hetero-zygote (GC) Prolin
Alanine (221 bp/288 bp)
No. = 4 No. = 9




Mean ± SD 4.06 ± 1.16 4.78 ± 1.18
Range 2.86–5.32 3.3–6.42




















Prevalence of genotypes and alleles among patients group compared to control group.
Genotype Patients group
No. %
Homozygote (CC) Proline/Proline 4 13.3%
Heterozygote (CG) Proline/Alanine 9 30.0%











Correlation between wild type allele (C) and mutant (G) allele regarding age and gender a
Item Wild (C)
No. = 17
Age (days) Mean ± SD 13.46 ± 5.83
Range 3–23
Sex Females 5 (38.50%)
Males 8 (61.50%)
* Insignificant.
** Highly significant.patients with neonatal sepsis and the normal control group as
regards prevalence of PPAR-c gene polymorphism in occurrence
of neonatal sepsis and its severity. The percentage of C allele
among patients group was nearly equally distributed between
homo- and heterozygosity while the G alleles was more in ten-
dency to be in homozygosity. On the other hand, the percentage
of G allele among control group was 5% and appeared in heterozy-
gosity only, while the percentage of C allele among control group
was 95% with more prevalence to be in homozygosity (90%), thus
there was statistical significant difference between patients group
and the control group which may suggest high risk for occurrence
of neonatal sepsis and PPAR-c G allele (Table 1).roup.





No = 17 F P-
value
P1 P2 P3
32.71 ± 22.45 0.355 0.704* 0.884 0.674 0.435
6–96
4.29 ± 1.06 0.804 0.458* 0.326 0.703 0.291
2.28–5.78
13.52 ± 3.37 0.527 0.596* 0.288 0.535 0.564
7.2–19.3
13.61 ± 6.88 1.212 0.313* 0.479 0.690 0.108
5.5–29.4
50.44 ± 19.92 0.094 0.910* 0.976 0.788 0.721
18.4–85.7
35.78 ± 17.38 0.422 0.660* 0.634 0.774 0.388
10.3–72.2
13.50 ± 12.31 0.037 0.964* 0.587 0.944 0.828
4–57
Control group Chi-square test
No. % X2 p-value
45 90.0% 50.612 0.000**
5 10.0%
0 0.0%








Mutant (G) Independent t-test
No. = 43 t P-value
7.88 ± 5.53 2.675 0.012**
2–25
6 (35.30%) 0.032 0.858*
11 (64.70%)
Table 4
Correlation between the segregated alleles and laboratory findings among patients group.
Laboratory findings Wild (C) Mutant (G) Independent t-test
No. = 17 No. = 43 t P-value
CRP (IU/UL) Mean ± SD 26.46 ± 16.09 32.71 ± 22.45 0.849 0.403*
Range 12–56 6–96
RBCS (‘106)/UL) Mean ± SD 4.56 ± 1.17 4.29 ± 1.06 0.655 0.518*
Range 2.86–6.42 2.28–5.78
Hb (g/dL) Mean ± SD 13.68 ± 2.94 13.52 ± 3.37 0.130 0.897*
Range 9.3–17.5 7.2–19.3
WBCS (‘103)/UL) Mean ± SD 10.28 ± 5.46 13.61 ± 6.88 1.434 0.163*
Range 4.4–25.2 5.5–29.4
Neutrophils (%) Mean ± SD 47.76 ± 10.06 50.44 ± 19.92 0.442 0.662*
Range 21.4–60 18.4–85.7
Lymphocytes (%) Mean ± SD 40.46 ± 9.67 35.78 ± 17.38 0.871 0.391*
Range 28.4–57.7 10.3–72.2
Monocytes (%) Mean ± SD Range 12.99 ± 4.00 6.9–20.9 13.50 ± 12.31 4–57 0.143 0.888*
* Insignificant.
Table 5
Correlation between clinical data and genotyping.
Clinical data Wild (CC + CG) Mutant (GG) Chi-square test
No. % No. % X2 P-value
Birth weight (kg) <1 1 16.7% 6 25.0% 18.722 0.000**
>2 4 66.7% 0 0.0%
1–2 1 16.7% 18 75.0%
Gestation Preterm 1 16.7% 20 83.3% 10.159 0.001**
Term 5 83.3% 4 16.7%
Neonatal fever Negative 4 66.7% 0 0.0% 18.462 0.000**
Positive 2 33.3% 24 100.0%
Depressed neonatal reflexes Depressed 1 16.7% 17 70.8% 5.868 0.015**
Normal 5 83.3% 7 29.2%
** Highly significant.
218 R.M. Shawky et al. / The Egyptian Journal of Medical Human Genetics 19 (2018) 215–220There was significant statistical difference between alleles
regarding age and neonatal sepsis (14 patients were early onset
neonatal sepsis and 16 patients were late onset neonatal sepsis)
while there was insignificant statistical difference between males
and females and neonatal sepsis. Early and late neonatal sepsis
occurred more with G allele (14 early-onset neonatal sepsis of
whom 10 were homozygote GG and 2 were heterozygote CG and
16 late onset neonatal sepsis of whom 7 were homozygote GG
and 7 were heterozygote CG (Table 2).
There was insignificant statistical difference for mean value of
CRP, RBCS, HB, WBCs, neutrophils, lymphocytes and monocytes
among patients group correlation with genotype. There was
insignificant statistical difference between alleles G and C in rela-
tion to CRP, WBCs, neutrophils, lymphocyte and monocytes among
patients group (Tables 3 and 4).
There was strong statistical relation between genotyping and
risk factors for neonatal sepsis: There was strong relation between
genotype GG and low birth weight, neonatal fever, prematurity and
depressed neonatal reflexes. Furthermore, the sepsis was more
severe with the risk factors which occurred mainly with the
mutant genotype (GG) within PPAR Gamma gene where all cases
with genotype GG died during the study (Table 5).
4. Discussion
The present study aimed to investigate the relationship
between the Pro12Ala polymorphism of PPAR gene and sepsis dis-
ease severity in a sample of Egyptian neonates (preterm and term).Recently, peroxisome proliferator activated receptor gamma
(PPAR-c) was described as playing a role in modulating the patho-
logical status of sepsis by regulating energy metabolism, inflam-
mation, and immune cell function and that PPAR-c has been
suggested to be beneficial in sepsis [4].
In the current study, patients with neonatal sepsis showed
strong significant prevalence of Ala allele (PPAR-c gene polymor-
phism) in comparison with controls regarding occurrence of
neonatal sepsis and its severity. It was demonstrated that the ben-
eficial effects of PPAR-c agonists appear to be mediated through the
down regulation of inflammatory responses, reduction of oxidative
stress, inhibition of apoptosis, and promotion of neurogenesis [10].
In our study, there was a strong relationship between (GC) (the
pro 12 Ala) genotype polymorphism in PPAR-c gene and occurrence
of neonatal sepsis (p < 0.01). The incidence of mutant allele in both
homozygosity (GG) and in heterozygosity (GC) together was
71.67%. On other hand, Ma et al. [11] found insignificant differ-
ences in the genotype distribution of the PPAR-c Pro12Ala variant
between the sepsis patients and healthy controls in the Chinese
Han population. Furthermore, they found that the frequency of
the mutant allele (G) in homozygosity alone (GG) (Pro12Pro) was
much higher (96.59%) than current study. In a study by Wang
et al., [12] on the effect of PPAR-b/d on sepsis-induced acute lung
injury, it was found that the PPAR-b/d agonist significantly
increased the survival of rats affected by sepsis, reduced histolog-
ical damage of the lungs, and decreased inflammatory cytokines in
serum and lung tissues of such affected rats with sepsis, however,
the counts of peritoneal bacteria did not increase. Over-expression
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alveolar macrophages. Yang et al. [13] reported that a PPARb/d ago-
nist has anti-inflammatory effects in experimental models of
atherosclerosis, myocardial ischemia and proteinuric kidney
disease.
In this study, the most prevalent genotype among our patients
was homozygote (GG) for polymorphic locus (coding for Alanine/
Alanine). This is in contrast to Ma et al., [11] who reported that
the frequency of (CC) genotype was the most prevalent (93.18%)
followed by GC (6.82%) in their patients group.
In our study, the percentage of G alleles among patient group
was detected in 71.66% with more tendency to be in homozygosity
(56.66%) compared to 5% only among control group where it
appeared in heterozygosity only (P < 0.05). This may suggest high
risk for occurrence of neonatal sepsis with PPAR-c G allele. Stratifi-
cation by subtypes (sepsis, septic shock, and severe sepsis)
revealed a statistically significant difference in the frequency of
the Ala allele and Ala-carrier genotype between the patients with
the sepsis subtype and the healthy controls [11].
The frequency of the Ala allele C in the sepsis subtype was sig-
nificantly higher than in the healthy controls and there were no
significant differences in genotype distribution or allele frequency
between the healthy controls and the septic shock or severe sepsis
subtype. So that the Pro12Ala polymorphism allele might not serve
as a marker for susceptibility to sepsis but could influence a
patient’s clinical outcome and risk of dying from sepsis. This is in
accordance with Ma et al., [10] who found that significant differ-
ences were found in the frequency of the Ala allele and genotype
between the sepsis survivors and non-survivors. In the survivors,
the PPAR-c Pro12Ala genotype was significantly associated with
decreased disease severity and recovery time. Gong et al. [14] sug-
gested that the Ala12 variant of PPAR-c has potential
gene-environment interactions. PPAR-c is expressed in the inflam-
matory cells involved in the progression of sepsis; monocytes,
macrophages and T-cells [15]. Some studies observed a protective
effect of the Ala allele in the carrier state [16].
Sun et al. [17] reported that the PPAR-c agonist Rosiglitazone
may ameliorate coagulation disorders in septic rats. PPAR-c/
NF-ΚB transduction pathway plays an important role in septic
coagulopathy. Brenneis et al. [18] reported that the level of perox-
isome proliferator-activated receptor c (PPARc) expression in T
cells from septic patients correlates with clinical outcome. Rosigli-
tazone increased bacterial clearance through PPAR c activation and
NET formation, combining immunomodulatory and host-
dependent anti-bacterial effects and, therefore, warrants further
study as a potential therapeutic agent in sepsis [19,20]. The poten-
tial role of PPARs in regulation of inflammation and angiogenesis is
intriguing and warrants further studies. Standage et al. [21]
reported that altered peroxisome proliferator-activated receptor-
a-mediated cellular metabolism may play an important role in
sepsis-related end-organ injury and dysfunction, especially in the
heart.
In our study, there was an insignificant statistical difference
between genotypes in correlation gender. This agrees with other
studies. However, The Ala12 allele frequency of the Pro12Ala SNP
varies different widely among ethnic groups [22].
The difference between genotypes for patients group was
statistically insignificant for mean value of CRP, RBCS, HB, WBCs,
neutrophils, lymphocytes and monocytes. For homozygote GG
there was a difference but not significant statistically for CRP
and WBCS. It was stated that lipoxin A4 up-regulated expression
of PPAR-c, as well as neutrophil gelatinase associated lipocalin
(NGAL) in adult neutrophils. In contrast, no effects were observed
in neutrophils from neonates. Moreover, constitutive expression
of PPAR-c was significantly reduced in neonatal neutrophils,
when compared with adult cells. These data suggest a potentialmechanism underlying persistent activation of neonatal neu-
trophils at inflammatory sites [23]. PPAR-b/d agonists and
PPARb/d adenovirus down-regulate TNF-a, IL-1b and IL-6 gene
expression [12].
5. Conclusion
There was a strong association between the Pro12Ala polymor-
phism in PPAR-c gene and the occurrence of neonatal sepsis. More-
over, (G) allele is considered as a risk factor for neonatal sepsis and
its severity, as well as PPAR-c gene has been suggested to be a
candidate gene for neonate sepsis. Therefore, Pro12Ala PPAR-c
polymorphism might be useful in predicting the risk of neonatal
sepsis and its severity.
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